PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation
Go online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experiences from their practice or research on relevant patient cases to guide learners on how to effectively impact treatment care and improve outcomes for patients with leukemia and lymphoma. Upon completion of this activity, participants should be better able to: Summarize the anticancer mechanism and the latest evidence on the efficacy and safety of adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in various lymphoma and leukemia settings, Assess the clinical role and benefits of CAR-T cell therapy within the context of HCT in eligible patients with leukemia and lymphoma, Apply appropriate strategies to manage the unique safety issues associated with CAR-T cell therapy in leukemia and lymphoma.